Gradual Weight Loss Microdosing semaglutide might result in more gradual weight loss over a longer period of time
Most commercially successful GLP-1 therapies continue to be administered through injectable formulations
Why Lipase Outperforms Amylase Higher sensitivity for acute pancreatitis Greater specificity for pancreatic pathology Remains elevated longer, providing a wider diagnostic window Less affected by non-pancreatic conditions Better correlation with pancreatic injury The Challenge with Amylase Can be elevated in salivary gland disease, renal impairment, gastrointestinal disorders, and macroamylasemia May normalize early, leading to missed diagnoses Lower specificity for pancreatic disease Limited value when used alone in modern pancreatitis workups In an era where laboratory medicine is increasingly evidence-driven, the question is no longer: "Can we measure amylase?" The real question is: "Does measuring amylase add meaningful clinical value when lipase is available?" As laboratory professionals, our responsibility extends beyond generating results, we must ensure that every test ordered contributes to accurate diagnosis, improved patient outcomes, and optimal resource utilization
agalactiae upregulates genes involved in fatty acid degradation during EMs progression
Our formulations utilize advanced liposomal delivery technology, ensuring optimal absorption and bioavailability
Seven large-scale trials are running
